Enhancing treatment outcomes after gynaecological cancer (ACUMEN): Using exercise to promote health after cancer therapy

Not Applicable

Recruiting

• Conditions: Cancer - Ovarian and primary peritoneal; Cancer - Cervical (cervix); Cancer - Other cancer types; Gynaecological cancer; Cancer - Womb (Uterine or endometrial cancer)

• Registration Number: ACTRN12621000050853
• Lead Sponsor: The University of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-19
• Last Update Posted: 19 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 342

Inclusion Criteria

1. Women > 18 years diagnosed with cancer of the ovary, cervix, Fallopian tubes, placenta, endometrium, vagina or vulva in the previous 60 months, including early, recurrent, advanced or metastatic cancer.
2. > 1 month since end of intensive cancer treatment (including surgery, radiotherapy, chemotherapy). Supportive therapies such as bisphosphonate, pain medication and hormone replacement allowable.
3. Resident in Australia.
4. Have access to the internet.
5. Own, or have access to, a computer, smart phone or tablet device.
6. Willing and able to comply with all study requirements, including intervention, timing and nature of required assessments.
7. Able to speak and read in English to ensure consent is informed and documentation of participant-reported outcome measures can be adhered to.
8. Can provide voluntary written informed consent.

Exclusion Criteria

1.Any clinical contraindication that precludes safe completion of the program in the judgement of the project team.
2.No intensive cancer treatments while enrolled.
3.In the care of an exercise professional at the time of enrolment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The mean difference on the physical component summary (PCS) scores of health-related quality of life between intervention and control in this trial, as measured by the Short Form-36 (SF36).[ Baseline (pre-intervention), week 12 (primary time-point, end of intervention) and week 24 (longer-term maintenance)];<br>The mean difference on the mental component summary (MCS) scores of health-related quality of life between intervention and control in this trial, as measured by the SF36.<br>[ <br>Baseline (pre-intervention), week 12 (primary time-point, end of intervention) and week 24 (longer-term maintenance).<br>]